N@N

Market Maker Surveillance Report. PSDV, GTXI, LXRX, FOLD, LIVE, SUPN, Winning Stocks With Lowest Price Friction For Tuesday, J

^{Published on 2012-06-26 18:00:52 - WOPRAI}
 

June 26, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3802 companies with "abnormal" market making, 2713 companies with positive Friction Factors and 2659 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. PSIVIDA CORP (NASDAQ:PSDV), GTX, INC. (NASDAQ:GTXI), LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX), AMICUS THERAPEUTICS INC (NASDAQ:FOLD), LIVEDEAL INC (NASDAQ:LIVE), (NASDAQ:SUPN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  PSDV    $0.370    19.68%    84,279       61.69%    49,832       36.48%    34,447       931     
  GTXI    $0.580    19.02%    212,686      55.65%    166,288      43.51%    46,398       800     
  LXRX    $0.320    16.41%    3,855,712    57.37%    2,862,471    42.59%    993,241      31,039  
  FOLD    $0.900    16.67%    79,435       52.22%    72,692       47.78%    6,743        75      
  LIVE    $1.310    16.38%    126,821      48.25%    122,506      46.61%    4,315        33      
  SUPN    $6.520    114.19%   1,754,214    50.15%    1,634,233    46.72%    119,981      184     

For example, the chart above shows PSDV with a dollar gain Tuesday of $0.37000 and a Friction Factor of 931 shares. That means that it only took 931 more shares of buying than selling to move PSDV higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

PSIVIDA CORP (NASDAQ:PSDV) - pSivida Corp., together with its subsidiaries, develops drug delivery products that are administered by implantation, injection, or insertion. The companys lead product candidate is Iluvien, which is in Phase III clinical trials and delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), a cause of vision loss. It is also conducting Phase II clinical trials with Iluvien in wet and dry age-related macular degeneration. In addition, the companys products include Retisert, an intravitreal drug implant for the treatment of chronic non-infectious posterior uveitis; and Vitrasert for cytomegalovirus retinitis, a blinding eye disease that occurs in individuals with advanced AIDS. It is developing a series of additional miniaturized, bioerodible technologies, including BioSilicon technology, which is nano-structured porous silicon designed for use as a drug delivery platform; and Medidur technology, a miniaturized, injectable, sustained-release drug delivery system to advance the treatment of medical conditions in critical areas, such as ophthalmology, oncology, and cardiology. Further, the companys BioSilicon product candidates includes BrachySil, a brachytherapy product in development for the treatment of solid tumors; and completed an initial safety study of BrachySil for the treatment of pancreatic cancer and a dose ranging study. It has strategic collaborations with Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

GTX, INC. (NASDAQ:GTXI) - GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia. The company is also developing selective androgen receptor modulators comprising Ostarine, which completed Phase II clinical trials for the treatment of cancer cachexia and chronic sarcopenia; and GTx-758, an oral luteinizing hormone that completed two Phase I clinical trials for the treatment of advanced prostate cancer. It has a partnership agreement with Ipsen S.A. for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy and toremifene 20 mg for the prevention of prostate cancer in patients with high grade prostatic intraepithelial neoplasia lesions. GTx, Inc. was founded in 1997 and is headquartered Memphis, Tennessee.

LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases in the areas of cardiology, gastroenterology, immunology, metabolism, and ophthalmology. The companys drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; and an alliance with Nuevolution A/S, which provides access to Nuevolutions Chemetics platform chemistry technology. Lexicon Pharmaceuticals, Inc. was formerly known as Lexicon Genetics Inc. and changed its name on April 26, 2007. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

AMICUS THERAPEUTICS INC (NASDAQ:FOLD) - Amicus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Its drugs are known as pharmacological chaperones, which selectively bind to the target protein, increase the stability of the protein, help it fold into the three-dimensional shape, and allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress. The company primarily focuses on lysosomal storage disorders and diseases of neurodegeneration. Its lead product candidate includes Amigal, which is in Phase III development for the treatment of Fabry disease. The company also develops AT2220, which is in Phase I testing for the treatment of Pompe disease. In addition, it develops Plicera for the treatment of Gaucher disease. The company was founded in 2002 and is based in Cranbury, New Jersey.

LIVEDEAL INC (NASDAQ:LIVE) - LiveDeal, Inc., together with its subsidiaries, delivers local customer acquisition services for small and medium-sized businesses. Its services are combined with an Internet Yellow Pages directory to deliver various ways for businesses via Internet through its online property, livedeal.com. The company, formerly known as YP Corp., was founded in 1968 and is headquartered in Las Vegas, Nevada.

(NASDAQ:SUPN) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net